AvantGen has licensed a panel of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development.
Aldevron has launched rep/cap plasmids to support adeno-associated virus (AAV) vector manufacturing.
AbSci, a synthetic biology company, has acquired Denovium, an artificial intelligence (AI) deep-learning company.
ImmunityBio has signed an exclusive worldwide licensing agreement for IosBio's OraPro vaccine platform technology that is currently being investigated in trials of ImmunityBio's second-generation human adenovirus 5 (hAd5) COVID-19 vaccine candidate.
Berkeley Lights has launched its Opto Plasma B Discovery 4.0 workflow for antibody discovery which can advance from B cells to lead molecules in one week.
Rocket Pharmaceuticals has announced the buildout for a new site in Cranbury, NJ, that will support Rocket's pipeline for lentivirus and adeno-associated virus (AAV) gene therapies.
Strand Therapeutics and BeiGene have entered into an option and license agreement in order to develop and commercialize Strand's messenger RNA (mRNA) treatments for solid tumors.
The first patient has been dosed in a phase I clinical trial being conducted by Codagenix and the Serum Institute of India of COVI-VAC, a single-dose, intranasal vaccine against the SARS-CoV-2 virus.
The U.S. Food and Drug Administration has granted orphan drug designation to Istari Oncology for its PVSRIPO technology as a treatment for stage IIB-IV melanoma.
Immunocore has completed $75 million in series C financing for the development of its novel T-cell receptor bispecific immunotherapies.
Insights
Exclusive content for Science Advisory Board members on trends and outcomes that are influencing the future of scientific research.
Communities
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Rewards
Earn points for contributing to research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Connect
